INTRODUCTION: Tumor-infiltrating lymphocytes (TILs) and forkhead box transcription factor positive (FoxP3(+)) regulatory T-lymphocytes (TREGs) have been analyzed in a variety of tumors but not in oesophageal adenocarcinoma. PATIENTS AND METHODS: Tissue from 130 adenocarcinomas of the oesophagus was re-evaluated in the centre and periphery of tumour, respectively, using immunohistochemical staining with anti-CD3, anti-CD4, anti-CD8, anti-CD25 and anti-FoxP3 antibodies. Patients were stratified according neoadjuvant treatment. 106 patients proceeded directly to surgery and 24 underwent pre-operative radio-chemotherapy (RCT). RESULTS: In patients without RCT, TILs were found significantly more frequently in the periphery with the exception of CD25(+) cells. Patients with centrally low counts of FoxP3(+) TREGs had higher tumour stages than patients with high counts (p < 0.011). The number of FoxP3(+) TREGs was significantly associated with the number of CD8(+) cells (centre: p < 0.001, periphery: p = 0.002). The multivariate regression analysis identified UICC stage (IIB/III vs. I/IIA, hazard ratio 2.6, p = 0.011) and completeness of resection (no vs. yes, hazard ratio 2.3, p = 0.015) as independent predictors of survival. RCT significantly reduced the number of TREGs in the centre (p = 0.016) but not the number of the other TILs. CONCLUSION: UICC stage and completeness of resection but none of the TILs were prognostic markers for long-term survival. We found no morphologic evidence that TREGs suppress immunological response, represented by the infiltration of CD8(+) cells. Preoperative RCT affected the centre of tumours more than the periphery, which may indicate that it does not inhibit the host-to-tumour reaction. RCT affects TREGs more than the other TILs.
INTRODUCTION: Tumor-infiltrating lymphocytes (TILs) and forkhead box transcription factor positive (FoxP3(+)) regulatory T-lymphocytes (TREGs) have been analyzed in a variety of tumors but not in oesophageal adenocarcinoma. PATIENTS AND METHODS: Tissue from 130 adenocarcinomas of the oesophagus was re-evaluated in the centre and periphery of tumour, respectively, using immunohistochemical staining with anti-CD3, anti-CD4, anti-CD8, anti-CD25 and anti-FoxP3 antibodies. Patients were stratified according neoadjuvant treatment. 106 patients proceeded directly to surgery and 24 underwent pre-operative radio-chemotherapy (RCT). RESULTS: In patients without RCT, TILs were found significantly more frequently in the periphery with the exception of CD25(+) cells. Patients with centrally low counts of FoxP3(+) TREGs had higher tumour stages than patients with high counts (p < 0.011). The number of FoxP3(+) TREGs was significantly associated with the number of CD8(+) cells (centre: p < 0.001, periphery: p = 0.002). The multivariate regression analysis identified UICC stage (IIB/III vs. I/IIA, hazard ratio 2.6, p = 0.011) and completeness of resection (no vs. yes, hazard ratio 2.3, p = 0.015) as independent predictors of survival. RCT significantly reduced the number of TREGs in the centre (p = 0.016) but not the number of the other TILs. CONCLUSION: UICC stage and completeness of resection but none of the TILs were prognostic markers for long-term survival. We found no morphologic evidence that TREGs suppress immunological response, represented by the infiltration of CD8(+) cells. Preoperative RCT affected the centre of tumours more than the periphery, which may indicate that it does not inhibit the host-to-tumour reaction. RCT affects TREGs more than the other TILs.
Authors: A Gentil Dit Maurin; C Lemercier; V Collin-Faure; P N Marche; E Jouvin-Marche; S M Candéias Journal: Clin Exp Immunol Date: 2015-01 Impact factor: 4.330
Authors: Reza Nejati; Jennifer B Goldstein; Daniel M Halperin; Hua Wang; Nazila Hejazi; Asif Rashid; Matthew H Katz; Jeffrey E Lee; Jason B Fleming; Jaime Rodriguez-Canales; Jorge Blando; Ignacio I Wistuba; Anirban Maitra; Robert A Wolff; Gauri R Varadhachary; Huamin Wang Journal: Pancreas Date: 2017-10 Impact factor: 3.327
Authors: Sandra Rauser; Rupert Langer; Sebastian Tschernitz; Peter Gais; Uta Jütting; Marcus Feith; Heinz Höfler; Axel Walch Journal: BMC Cancer Date: 2010-11-05 Impact factor: 4.430
Authors: M Schoemmel; H Loeser; F Gebauer; A Quaas; M Kraemer; S Wagener-Ryczek; A Hillmer; C Bruns; M Thelen; W Schröder; T Zander; A Lechner; R Buettner; H Schlösser Journal: Clin Transl Oncol Date: 2021-02-10 Impact factor: 3.405
Authors: S Dutta; J J Going; A B C Crumley; Z Mohammed; C Orange; J Edwards; G M Fullarton; P G Horgan; D C McMillan Journal: Br J Cancer Date: 2012-01-12 Impact factor: 7.640